Nabi Biopharmaceuticals

--------------------------------------------------------------------------------

EXHIBIT 10.52

STATEMENT UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The undersigned officers of Nabi Biopharmaceuticals (the “Company”) hereby
certify that, as of the date of this statement, the Company’s quarterly report
on Form 10-Q for the quarter ended September 28, 2002 (the “Report”) fully
complies with the requirements of section 13(a) of the Securities Exchange Act
of 1934 and that information contained in the Report fairly presents, in all
material respects, the financial condition and results of the Company as of and
for the three- and nine-month periods ended September 28, 2002.

The purpose of this statement is solely to comply with Title 18, Chapter 63,
Section 1350 of the United States Code, as amended by Section 906 of the
Sabarnes-Oxley Act of 2002. This statement is not “filed” for the purposes of
Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Act or any other federal or state law or regulation.

      Date: October 30, 2002   /s/ David J. Gury    

--------------------------------------------------------------------------------

    Name: David J. Gury     Title: Chief Executive Officer       Date: October
30, 2002   /s/ Mark L. Smith    

--------------------------------------------------------------------------------

    Name: Mark L. Smith     Title: Chief Financial Officer

21